{"filing":{"accession_number":"0001193125-26-286918","cik":"0002044725","ticker":"EVMN","company_name":"Evommune, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"evmn-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526286918/evmn-20260629.htm"},"events":[{"id":14499,"run_id":12912,"accession_number":"0001193125-26-286918","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Evommune announced that its Phase 2b clinical trial of EVO756 failed to meet its primary endpoint in chronic spontaneous urticaria, leading the company to cease development in this indication while continuing evaluation in atopic dermatitis and migraine. This material clinical development setback represents a significant strategic pivot affecting the company's pipeline and investor assessment of its progress.","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11959,"accession_number":"0001193125-26-286918","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced top-line results from a Phase 2b clinical trial of EVO756 that failed to meet its primary endpoint in chronic spontaneous urticaria, though the company is continuing development in other indications (atopic dermatitis and migraine). This is a material clinical development milestone—a negative trial result that affects the company's pipeline strategy—but does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature, relating to the company's drug development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:33:40.531602+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11960,"accession_number":"0001193125-26-286918","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces top-line results from a Phase 2b clinical trial of EVO756 in chronic spontaneous urticaria that failed to meet its primary endpoint, leading the company to cease development of the drug in this indication. This is a material operational/clinical development event for a clinical-stage biotech company, as it represents a significant setback in the pipeline and a strategic decision to redirect resources. While the company will continue evaluating EVO756 in other indications (atopic dermatitis and migraine), the failure of this trial and the decision to halt CSU development materially affects investor assessment of the company's progress and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:33:40.531602+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11959,"accession_number":"0001193125-26-286918","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced top-line results from a Phase 2b clinical trial of EVO756 that failed to meet its primary endpoint in chronic spontaneous urticaria, though the company is continuing development in other indications (atopic dermatitis and migraine). This is a material clinical development milestone—a negative trial result that affects the company's pipeline strategy—but does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature, relating to the company's drug development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:33:40.531602+00:00","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-06-29"},{"id":11960,"accession_number":"0001193125-26-286918","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces top-line results from a Phase 2b clinical trial of EVO756 in chronic spontaneous urticaria that failed to meet its primary endpoint, leading the company to cease development of the drug in this indication. This is a material operational/clinical development event for a clinical-stage biotech company, as it represents a significant setback in the pipeline and a strategic decision to redirect resources. While the company will continue evaluating EVO756 in other indications (atopic dermatitis and migraine), the failure of this trial and the decision to halt CSU development materially affects investor assessment of the company's progress and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T12:33:40.531602+00:00","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-06-29"}]}